R-Biopharm Inc.
R-Biopharm Inc., a prominent player in the biotechnology sector, is headquartered in the United States, with significant operations across North America and Europe. Founded in 1988, the company has established itself as a leader in the development of innovative diagnostic solutions, particularly in the fields of food safety, clinical diagnostics, and veterinary medicine. R-Biopharm's core offerings include a diverse range of enzyme immunoassays, PCR kits, and rapid tests, which are distinguished by their high sensitivity and specificity. The company’s commitment to quality and innovation has earned it a strong market position, recognised for its contributions to enhancing public health and safety. With a focus on research and development, R-Biopharm continues to achieve notable milestones, solidifying its reputation as a trusted partner in the global biotechnology landscape.
DitchCarbon Score
How does R-Biopharm Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Education Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
R-Biopharm Inc.'s score of 27 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
R-Biopharm Inc.'s reported carbon emissions
In 2022, R-Biopharm Inc. reported total carbon emissions of approximately 128,990 kg CO2e, a reduction from about 162,710 kg CO2e in 2021. The emissions breakdown for 2022 includes Scope 1 emissions of about 4,560 kg CO2e, primarily from mobile combustion, and Scope 2 emissions of approximately 89,310 kg CO2e. Notably, Scope 3 emissions were significant, with business travel contributing about 23,320 kg CO2e. R-Biopharm's commitment to reducing its carbon footprint is evident in its ongoing efforts, although specific reduction targets or initiatives have not been detailed. The company has demonstrated a decrease in emissions intensity, with GHG emissions per annual revenue dropping from 0.016 in 2021 to 0.013 in 2022, indicating a more efficient operation relative to its revenue generation. Overall, R-Biopharm Inc. is making strides towards sustainability, with a focus on reducing emissions across its operations, although further clarity on specific climate commitments would enhance understanding of its long-term environmental strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 7,940 | 0,000 |
| Scope 2 | 95,480 | 00,000 |
| Scope 3 | 2,610 | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
R-Biopharm Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
